Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KIT A502_Y503dup |
| Therapy | Imatinib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KIT A502_Y503dup | Advanced Solid Tumor | sensitive | Imatinib | Preclinical - Biochemical | Actionable | In a preclinical study, Gleevec (imatinib) treatment decreased Kit autophosphorylation in cells expressing KIT A502_Y503dup (referred to as Y503_F504insAY) in culture (PMID: 14645423). | 14645423 |
| KIT A502_Y503dup | Advanced Solid Tumor | sensitive | Imatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing KIT A502_Y503dup (Y503_F504insAY) were sensitive to Gleevec (imatinib) in culture, demonstrating decreased cell proliferation (PMID: 24205792). | 24205792 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (24205792) | Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. | Full reference... |
| (14645423) | Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. | Full reference... |